GeLongHui November 19th | cabio biotech(wuhan) (688089.SH) stated on the interactive platform that the company has already developed a series of HMOs products including 2’-FL, 3-FL, 3’-SL, 6’-SL, LNnT, and has conducted related patent layout. According to the company's disclosed 2024 interim report, LNnT has completed the optimization of pilot-scale fermentation process and entered the pilot-scale testing phase. Other company-related patents are unrelated to our company.
嘉必优(688089.SH)：LNnT已完成小试发酵工艺优化，进入中试阶段
Cabio biotech(wuhan) (688089.SH): LNnT has completed the optimization of the small-scale fermentation process and has entered the pilot test stage.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated